This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Its T cells in particular are famous for their ability to attack tumors, leading to immunotherapies that have revolutionized cancer treatment. Immunologist Lloyd Bod will take us on a tour of the immune system, and discuss new insights that may help scientists and doctors leverage its cancer-fighting capabilities more effectively.
In this IO arena, we continue to search for additional treatments that can further benefit patients. Generally, IO has been focused on harnessing the anti-tumour activity of certain cancer-fighting T-cells , a key cell type involved in the adaptive immune defense system.
This is an unprecedented opportunity to evaluate how immuneresponses work,” said Robert Manguso , who is co-senior author on the study, an associate member at the Broad, and an assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard MedicalSchool.
25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immuneresponse that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. MONDAY, Jan. SOURCES: Patrick A.
This approach capitalizes on prior investments in R&D, mitigates risk by leveraging established safety and pharmacokinetic profiles, and accelerates the delivery of treatments to patients. For example, researchers utilized gene expression data to determine the anti-ulcer drug cimetidine as a possible treatment for colorectal cancer.
In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medicalschool. The human monoclonal antibody targets specific immune plasma cells. Treatment induced sustainable clinical responses and reduced systemic inflammation.
Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. NH: This is the first single-cell resolution dictionary of each major immune cell type responding to each major cytokine in vivo at an unprecedented scale.
Monoclonal antibodies (mAbs) targeting tumour-specific antigens play an essential role in the treatment of many cancers. To be therapeutically useful, antigenic peptides must be presented in a way that allows immuneresponses to destroy cancer cells without causing unacceptable damage to healthy tissue.
Researchers from Harvard MedicalSchool describe a new ChatGPT-like model that can guide clinical decision-making to diagnose, treat, and predict survival for several types of cancer. This removes the cancer’s blocking of the immuneresponse, so that T cells can fight the cancer. Their report appears in Nature.
Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts MedicalSchool (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs.
Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard MedicalSchool (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.
Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated.
This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses.
NEW YORK and LONDON, Jan.
NEW YORK and LONDON, Jan.
When infused back into a mouse model of MS, the backpack-laden monocytes were able to affect MS-specific immuneresponses, and partially reverse hind limb paralysis and improve motor functions. The results are published in the Proceedings of the National Academy of Sciences (PNAS).
Trial facilitated with coll a boration of Harvard MedicalSchool and one of the world’s top Neurologist, Dr. Howard Weiner.
Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug.
Clinical Data Expected by End of Year.
NEW YORK and LONDON, Nov.
By Leah Eisenstadt November 6, 2024 Credit: Ricardo Job-Reese, Broad Communications Despite being one of the rarer complications from immune checkpoint inhibitors, myocarditis is the most deadly. In addition, treatments and supportive care approaches used for other forms of myocarditis, such as viral myocarditis, don’t work for this type. “We
These patients had been given the revolutionary immunotherapy drugs known as immune checkpoint inhibitors (ICIs), which take the brakes off the body’s immune system so that it can fight cancer. With immunotherapy, it awakens your immune system in a way that’s like a fire in a bush — it doesn’t stop.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content